Protein-Protein interactions (PPIs) are central to most essential cellular mechanisms including gene expression, protein translocation, cell cycle progression and signal transduction. Bellón-Echeverría et al. published in Scientific Reports a proof of concept employing MultiBacMam to identify new small-molecule inhibitors of the CDK5-p25 protein-protein interaction. The method is generally applicable to any multiprotein cascade important in drug discovery.
Stolt-Bergner et al. published in Journal of Structural Biology a benchmarking initiative in 13 independent labs to compare the world’s leading baculovirus expression systems. Geneva Biotech’s EMBacY virus was ranked #1 in performance.
Tchesnokov et al. published in Scientific Reports (DOI: :10.1038/s41598-018-22328-3) a production system for Ebola Virus RNA-Dependent RNA Polymerase Complex using the MultiBac system, providing a powerful discovery system for this key drug target.
Geneva Biotech and Sphere Fluidics launch R&D project to develop methods that enable large DNA cargo delivery and genome engineering in primary cells that have proven refractory to traditional transfection, electroporation, or transduction methods. LINK
Geneva Biotech and partners have recorded >70% increase in baculovirus DNA stability in scale up experiments to 100L using second generation SynBac genomes. DNA stability was found to strongly correlate (r = 0.91) with expression yield of multiple different test proteins.
Intact Genomics is a world leader of ultra-high competent cell production and BAC (bacterial artificial chromosome) library related technologies. Intact has partnered with Geneva Biotech to offer North American customers competent cells containing Geneva Biotech’s viral genomes. See their Geneva Biotech partnered products here INTACT GENOMICS
Aylett et al. published in Science (DOI: 10.1126/science.aaa3870) the structure of key drug target mTORC1 using the MultiBac system, providing critical information on the function and intricate regulation of this important enzyme which is implicated in common human diseases including cancer and diabetes.
Genetic code expansion (GCE) is a powerful method to incorporate artificial amino acids into polypeptide chains to create synthetic proteins with novel functions, with many applications ranging from discovery science to molecular medicine.
Until recently, this method has been mostly confined to small individual proteins representing a limited repertoire of cellular activity. Biological function in humans, however, is typically catalyzed by large protein machines, often comprising ten or more individual protein subunits. An international team of scientists from University of Bristol, EMBL and the Karlsruhe Institute of Technology have now developed MultiBacTAG, a powerful system to enable genetic code expansion in complex multiprotein machines.
Developed by the European Union ComplexINC R&D consortium, Kinase Factory™
is a baculovirus expression system where entire 5-8 protein chaperone machineries specific for protein kinase folding were integrated into synthetic baculovirus genomes to provide a unique platform for production of kinases that display poor folding or stability. The system is also ideal for boosting production yields of kinases for large scale expression, e.g. for target production for drug discovery.
Developed by the European Union ComplexINC R&D consortium, Hormone Receptor Factory™
is a baculovirus expression system where entire 5-7 protein chaperone machineries specific for hormone folding were integrated into synthetic baculovirus genomes to provide a unique platform for production of hormone receptors that display poor folding or stability. The system is also ideal for boosting production yields of hormone receptors for large scale expression, e.g. for target production for drug discovery.